AU
UK
CA
NZ
IND
US
Shuttle Pharmaceuticals Holdings(NASDAQ:SHPH)continues to advance its lead candidate, Ropidoxuridine (IPdR), a drug designed to selectively sensitize cancer cells to radiation while protecting healthy tissue. The compound is currently under investigation in glioblastoma, one of the most aggressive brain cancers.
Pfizer Inc. (NYSE:PFE) has released updated follow-up results from the Phase 2 PHAROS trial, evaluating the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for adults with metastatic non-small cell lung cancer (mNSCLC) carrying the BRAF V600E mutation. In treatment-naïve participants, median overall survival (OS) …
Equities research analysts have recently adjusted their ratings for Lucid Diagnostics (NASDAQ:LUCD). Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating in a report released Tuesday. Needham & Company LLC maintained a "buy" rating and set a USD 3.00 …
NovoCure Limited (NASDAQ:NVCR) has received an average recommendation of“Hold”from eight analysts covering the company, as reported by MarketBeat Ratings. Of these analysts, one assigned a“Sell”rating, three rated it as“Hold,”and four gave a“Buy”rating. The collective 12-month price target across these brokerages averages USD 27.50.
William Blair reiterated its outperform rating on Autolus Therapeutics (NASDAQ:AUTL), reinforcing a broadly positive analyst sentiment for the clinical-stage biotech firm. Needham & Company echoed this view with a “buy” rating and a USD 10.00 price target, while Wells Fargo trimmed its target to …
Organogenesis Holdings Inc. (Nasdaq:ORGO) announced an update on its second Phase 3 randomized controlled trial (RCT) of ReNu®, a cryopreserved amniotic suspension allograft (ASA) for symptomatic knee osteoarthritis (OA). While the study did not achieve statistical significance for its primary endpoint, the results showed …
Biotech stocks made headlines on Thursday, September 25, 2025, with standout performances driven by unique company developments and promising clinical progress. Despite a challenging market environment, PepGen Inc., HeartSciences Inc., and Jasper Therapeutics delivered remarkable gains, fueled by innovation, strategic pivots, and investor optimism. …
Evaxion A/S (NASDAQ:EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, announced that MSD (Merck & Co., Inc.) has exercised its option to license the vaccine candidate EVX-B3. As part of the agreement, Evaxion receives a $7.5 million cash payment and is eligible …
JPMorgan Chase & Co. increased its target price for Roivant Sciences Ltd. (NASDAQ:ROIV) from USD 16.00 to USD 20.00 in a research note issued on Thursday, according to Benzinga. The brokerage maintained an “overweight” rating, citing potential upside of 32.98% based on the stock’s …
Harrow (NASDAQ:HROW) operates in the healthcare sector. It provides laboratory testing, clinical services, and related solutions. The company focuses on diagnostics, personalized medicine, and laboratory services across several therapeutic areas.
Please wait processing your request...